The Motley Fool

CSL’s shares sold off

Global biotherapy firm CSL (ASX: CSL) reported a strong set of financial results for the full year to June 2013 on Wednesday, however it’s been an unpleasant week for the company’s share price.

After opening Monday morning at $65.55, by the close of trade on Tuesday the stock had climbed to within a whisker of its all-time high of $68 in anticipation of the results. On Wednesday morning, with the results released to the market, the stock opened down 3% at $65.66 with that downtrend continuing through the rest of the week. By midday Friday the stock was trading at $63.37, down around 6.5% from the high reached on Tuesday.

To recap, these were the highlights from CSL’s results:

  • Sales rose 7% to US$5 billion
  • Earnings before interest and tax rose 17% to US$1,486 million
  • Net profit after tax rose 19% to US$1,216 million
  • Earnings per share rose 24% thanks to an on-going share buyback to US$2.44
  • Final dividend declared of US$0.52 cents per share, taking the full year dividend to US$1.02 per share, up 18% on the prior year.
  • The board announced it would consider a further share buyback

CSL’s management said the next 12 months would be tough and provided guidance for financial year (FY) 2014 of net profit after tax (NPAT) to grow by 10% with earnings per share (EPS) growth to exceed NPAT growth thanks to past and proposed management initiatives. Assuming this could lead to EPS growth in FY2014 of approximately 15%, an EPS figure of A$3.07 at current exchange rates could be expected. This places CSL on a forward price-to-earnings (PE) multiple of 20.7.

It’s been a mixed results season so far for investors in the healthcare sector. Shareholders in Cochlear (ASX: COH) were faced with a fall in earnings, however a boost from a new product release should see a stronger FY2014 result. While Resmed (ASX: RMD) continued its history of strong growth and surprised shareholders with a big increase in its dividend.

Foolish takeaway

Healthcare stocks have a history of selling at lofty valuations. Often this is justified but it does mean shareholders need to be extra vigilant. CSL shareholders currently need to be asking themselves if a PE multiple of over 20 times — given EPS growth of possibly 15% — is justified.

Looking for a less risky alternative? Interested in our #1 dividend-paying stock? Discover The Motley Fool’s favourite income idea for 2013-2014 in our brand-new, FREE research report, including a full investment analysis! Simply click here for your FREE copy of “The Motley Fool’s Top Dividend Stock for 2013-2014.”

More reading

Motley Fool contributor Tim McArthur does not own shares in any of the companies mentioned in this article.

NEW. Five Cheap and Good Stocks to Buy in 2019…

Our Motley Fool experts have just released a brand new FREE report, detailing 5 dirt cheap shares that you can buy today.

One stock is an Australian internet darling with a rock solid reputation and an exciting new business line that promises years (or even decades) of growth… while trading at an ultra-low price…

Another is a diversified conglomerate trading near a 52-week low all while offering a 2.8% fully franked yield…

Plus 3 more cheap bets that could position you to profit over the next 12 months!

See for yourself now. Simply click the link below to scoop up your FREE copy and discover all 5 shares. But you will want to hurry – this free report is available for a brief time only.